Xanthine Oxidase

Xanthine oxidase-IN-4 is a potent inhibitor of xanthine oxidase (XO), exhibiting an IC50 of 0.039 μM. This compound demonstrates significant hypouricemic activity in potassium oxonate-induced models of hyperuricemia, making it suitable for investigations related to hyperuricemia and gout. Xanthine oxidase-IN-4 is valuable for researchers studying metabolic disorders and the pharmacological management of gout.

5,6,7-Trihydroxy-4'-methoxyflavone, also known as 4'-O-Methylscutellarein, is a flavonoid that acts primarily as an antithrombotic agent. It exhibits both antithrombotic and antioxidant properties, with an IC50 of 25.29 µM for scavenging DPPH free radicals. Additionally, this compound effectively inhibits H2O2-induced damage in PC12 cells, making it a valuable reagent for studying cerebrovascular disorders and related conditions.

Protosappanin A dimethyl acetal is a homoisoflavonoid that acts as a competitive inhibitor of xanthine oxidase. This compound demonstrates significant xanthine oxidase inhibitory activity, with an IC50 value of 50.7 μM. It is isolated from the plant species Caesalpinia sappan and is applicable in research focused on oxidative stress and related metabolic disorders.

Xanthine oxidase-IN-15 is a selective inhibitor of xanthine oxidase (XO) with an IC50 of 0.13 μM. This compound functions by forming a stable interaction at the active site of XO, effectively inhibiting its catalytic activity. Xanthine oxidase-IN-15 is primarily utilized in research related to hyperuricemia and gout, offering insights into the management and treatment of these conditions.

Renierol is an orally active inhibitor of xanthine oxidase (XO), a critical enzyme involved in purine metabolism. It exhibits notable urate-lowering activity, making it valuable for research related to gout and hyperuricemia. This compound is essential for studying the role of XO in oxidative stress and related pathologies.

5-Hydroxy-3,4,7-triphenyl-2,6-benzofurandione is a potent inhibitor of xanthine oxidase, an enzyme involved in the oxidative metabolism of purines. This compound exhibits significant biological activity in the reduction of uric acid levels, making it relevant for studies related to hyperuricemia and gout. Research applications include investigations into the mechanistic pathways of oxidative stress and potential therapeutic interventions for related disorders.

BOF-4272 is a selective inhibitor of xanthine oxidase and xanthine dehydrogenase. This compound is primarily utilized in research focused on hyperuricemia and related disorders. By inhibiting uric acid production, BOF-4272 serves as a valuable tool for studying gout and other conditions associated with elevated uric acid levels.

Hydroxyakalone is a potent inhibitor of xanthosine oxidase (XOD, EC 1.2.3.2), exhibiting an IC50 value of 4.6 μM. This compound is useful in research applications focused on oxidative stress and related metabolic pathways. Its ability to inhibit XOD may provide insights into the management of conditions associated with elevated levels of xanthine and uric acid.

Amflutizole is a potent inhibitor of xanthine oxidase, effectively reducing the formation and release of free radicals. This compound demonstrates protective effects in models of cerebral ischemia/reperfusion, making it a valuable tool for research into oxidative stress and related neuroprotective strategies. Its ability to modulate xanthine oxidase activity positions it for applications in studying various neurological conditions and therapeutic interventions.

Xanthine oxidase-IN-14 is a potent inhibitor of xanthine oxidase, demonstrating an IC50 value greater than 100 μM. This compound has shown significant anti-proliferative activity against cancer cell lines, including MCF-7, NCI-H460, and SF-268, with inhibition occurring at an IC50 greater than 150 μM. It serves as a valuable tool for exploring the role of xanthine oxidase in cancer biology and potential therapeutic applications.

Xanthine oxidase-IN-22 is a potent inhibitor of xanthine oxidase (XO) with an IC50 of 0.0034 μM, demonstrating a mixed-type inhibition profile. This compound effectively lowers serum uric acid levels in murine models. Xanthine oxidase-IN-22 is suitable for research applications focused on hyperuricemia and gout management.

Xanthine oxidase-IN-1 is a potent inhibitor of xanthine oxidase, demonstrating an IC50 of 6.5 nM. This compound is valuable for research applications focusing on the modulation of purine metabolism and the investigation of conditions associated with oxidative stress, such as gout and cardiovascular diseases. Its ability to effectively inhibit xanthine oxidase makes it a useful tool in exploring therapeutic strategies for these disorders.